
Novartis to acquire Excellergy to accelerate next-gen anti-IgE therapy
Novartis will acquire Excellergy for up to USD 2 billion in upfront and milestone payments to bolster its immunology portfolio with Exl-111, a Phase 1, half-life–extended anti-IgE antibody designed to dissociate receptor-bound IgE and drive faster, deeper IgE signaling suppression. If approved, Exl-111 could improve symptom control and dosing convenience across IgE‑driven diseases such as food allergy, chronic urticaria, inducible urticaria and asthma; closing is targeted for H2 2026, subject to regulatory approvals.













